£3.3M
The Stevenage enterprise raised the capital from Longwall Ventures and a syndicate of backers to fund trials and product development.
"Advanced therapy manufacturing is hindered by out of date, inadequate manufacturing technologies,"
Portfolio
3
companies
By category
- FoodTech£7.4M
- BioTech£6.2M
By location
- London£7.4M
- Stevenage£3.3M
- Deeside£2.9M
Portfolio companies
M
MicrofluidX
MicrofluidX provides next-generation bioreactors for cell research and manufacturing.
RB
Reacta Biotech
Produces standardised diagnostic kits for clinical food allergy testing.
S
Sessions
Sessions supports independent food talent through a cross-channel culinary platform.
Team
JM
Jon Moulton
Private Investor
Jon brings administrative and investment experience from roles at J.P. Morgan, Perscitus, and Greenland Holding Group. He also operates as a private investor at Perscitus.
CS
Charles Shorthand
Recent investments
£7.4M
Guinness Asset Management led the Series A round to support team expansion and kitchen network growth.
"We are proud to take investment from such a forward-thinking, collaborative fund as Guinness. Our purpose is to be a voice for the independents, championing change and empowerment, and it’s great to see our new partners entirely bought into that mission."
£2.9M
The funding round was led by Praetura Ventures with participation from the Development Bank of Wales and Perscitus.
"It’s been a landmark year for Reacta, and we continue to go from strength-to-strength as a business, developing new diagnostic products and expanding our capabilities. The number of people experiencing food allergies is increasing, so it’s vital that technologies to accurately and safely test for allergies are developed. We’re committed to providing excellence in the development of a suite of OFC products, and revolutionising the way food allergies are diagnosed worldwide."
